Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$12.56 +1.2%	$11.25	$3.98 ▼ $13.37	$1.91B	1.92	2.05 million shs	2.20 million shs
DNLI Denali Therapeutics	$14.81 -0.1%	$14.30	$10.57 ▼ $33.33	$2.17B	1.36	1.41 million shs	974,998 shs
MESO Mesoblast	$15.14 -5.0%	$13.13	$6.00 ▼ $22.00	$1.94B	2.4	278,129 shs	193,819 shs
ORKA Oruka Therapeutics	$14.56 -4.5%	$13.40	$5.49 ▼ $52.32	$545.29M	-0.35	249,067 shs	221,349 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-4.83%	+2.14%	+19.44%	+32.59%	+156.94%
DNLI Denali Therapeutics	+0.82%	+6.52%	+5.86%	+3.71%	-35.62%
MESO Mesoblast	-1.97%	+8.37%	+1.98%	+38.04%	+139.19%
ORKA Oruka Therapeutics	-0.78%	+16.86%	+4.88%	+43.60%	+1,524,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.2447 of 5 stars	1.4	1.0	4.2	1.4	1.7	0.6
DNLI Denali Therapeutics	4.1274 of 5 stars	3.6	1.0	4.7	2.9	3.3	0.0
MESO Mesoblast	1.901 of 5 stars	2.6	4.0	0.0	2.0	0.8	0.6
ORKA Oruka Therapeutics	2.4854 of 5 stars	3.6	0.0	0.0	1.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-1.47% Downside
DNLI Denali Therapeutics	3.12	Buy	$33.62	126.98% Upside
MESO Mesoblast	3.20	Buy	$18.00	18.89% Upside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	177.30% Upside

Current Analyst Ratings Breakdown

Latest ORKA, MESO, DNLI, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/18/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
8/12/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
8/5/2025	MESO Mesoblast	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/23/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/21/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
7/18/2025	MESO Mesoblast	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$205.22M	9.32	N/A	N/A	$1.37 per share	9.17
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$8.53 per share	N/A
MESO Mesoblast	$5.67M	341.78	N/A	N/A	$4.21 per share	3.60
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$10.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/27/2025 (Estimated)
ORKA Oruka Therapeutics	-$83.72M	-$2.81	N/A	N/A	N/A	N/A	-26.26%	-24.16%	N/A

Latest ORKA, MESO, DNLI, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	H2 2025	MESO Mesoblast	-$0.20	N/A	N/A	N/A	$7.48 million	N/A
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/11/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.48	-$0.46	+$0.02	-$0.46	N/A	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
DNLI Denali Therapeutics	0.01	10.27	10.27
MESO Mesoblast	0.22	0.96	0.63
ORKA Oruka Therapeutics	N/A	27.42	27.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
DNLI Denali Therapeutics	92.92%
MESO Mesoblast	1.43%
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
DNLI Denali Therapeutics	12.50%
MESO Mesoblast	18.80%
ORKA Oruka Therapeutics	24.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
MESO Mesoblast	80	128.00 million	103.93 million	Optionable
ORKA Oruka Therapeutics	N/A	37.45 million	28.20 million	N/A

ORKA, MESO, DNLI, and ADPT Headlines

Recent News About These Companies

Oruka Therapeutics (ORKA) Receives a Buy from H.C. Wainwright

5 hours ago | theglobeandmail.com

Oruka Therapeutics (NASDAQ:ORKA) Rating Lowered to "Sell" at Wall Street Zen

August 18 at 2:33 AM | americanbankingnews.com

Wedbush Forecasts Reduced Earnings for Oruka Therapeutics

August 17 at 8:58 AM | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Downgraded by Wall Street Zen to "Sell"

August 17 at 2:40 AM | marketbeat.com

Q3 EPS Estimate for Oruka Therapeutics Lowered by Analyst

August 17 at 2:23 AM | americanbankingnews.com

Q3 EPS Forecast for Oruka Therapeutics Reduced by Analyst

August 16 at 8:21 AM | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth Plans

August 15, 2025 | finance.yahoo.com

Oruka Therapeutics (NASDAQ:ORKA) Trading 7.1% Higher - Here's Why

August 15, 2025 | marketbeat.com

Leerink Partnrs Has Pessimistic View of ORKA Q3 Earnings

August 15, 2025 | americanbankingnews.com

Wedbush Reiterates "Outperform" Rating for Oruka Therapeutics (NASDAQ:ORKA)

August 14, 2025 | americanbankingnews.com

Oruka Therapeutics' (ORKA) "Outperform" Rating Reiterated at Wedbush

August 13, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

August 12, 2025 | marketbeat.com

Oruka Therapeutics reports Q2 EPS (46c), consensus (43c)

August 12, 2025 | msn.com

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025 | globenewswire.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of "Buy" from Analysts

August 10, 2025 | marketbeat.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by Brokerages

August 9, 2025 | americanbankingnews.com

Oruka Therapeutics (NASDAQ:ORKA) Trading Down 9.4% - Here's Why

August 7, 2025 | marketbeat.com

TD Asset Management Inc Decreases Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Grows Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

August 3, 2025 | marketbeat.com

Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday

July 31, 2025 | marketbeat.com

Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug

July 22, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, MESO, DNLI, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$12.56 +0.15 (+1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$12.56 0.00 (0.00%)

As of 06:58 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Denali Therapeutics NASDAQ:DNLI

$14.81 -0.01 (-0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$14.83 +0.02 (+0.14%)

As of 04:49 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Mesoblast NASDAQ:MESO

$15.14 -0.79 (-4.96%)

Closing price 04:00 PM Eastern

Extended Trading

$15.14 0.00 (0.00%)

As of 07:11 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Oruka Therapeutics NASDAQ:ORKA

$14.56 -0.69 (-4.52%)

Closing price 04:00 PM Eastern

Extended Trading

$14.57 +0.01 (+0.07%)

As of 05:13 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time